Please try another search
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Mark J. Gergen | 61 | 2018 | Executive Chairman of the Board |
Cynthia L. Collins | 66 | 2021 | Independent Director |
John P. Schmid | 61 | 2018 | Lead Independent Director |
Luca Gattinoni | - | 2021 | Member of Scientific Advisory Board |
Luke David Corning | 42 | 2020 | Independent Director |
Mark A. Kay | 65 | 2023 | Member of Gene Therapy Scientific Advisory Board |
Marcea Bland Lloyd | 75 | 2019 | Independent Director |
Carl H. June | 69 | 2021 | Chairman of Cell Therapy Scientific Advisory Board |
Jan Joseph Melenhorst | - | 2021 | Member of Scientific Advisory Board |
Christine Brown | - | 2021 | Member of Scientific Advisory Board |
Julian Grunewald | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Kathryn A. Whitehead | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Ian E. Alexander | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Charles M. Baum | 66 | 2022 | Independent Director |
Rafael G. Amado | 60 | 2023 | Director |
George McDonald Church | 70 | 2022 | Chairman of Gene Therapy Scientific Advisory Board |
Mark Tracy | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Kristin Yarema | 53 | 2023 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review